Revised 2018 Child and Adolescent Vaccine Schedule Released by ACIP
February 6th 2018The updated 2018 immunization schedule for children and teens has been released by the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP).
Combo Inhibitor Antibiotic Approved to Treat HABP/VABP
February 3rd 2018The US Food and Drug Administration has approved Allergan's supplemental New Drug Application to expand the approved use of their cephalosporin / beta-lactamase inhibitor combo antibiotic, AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-negative microorganisms.
DEA Action Supports NP, PA Prescribing Authority for Opioid Addiction Treatment
January 23rd 2018A new measure announced by the Drug Enforcement Administration (DEA) will expand access to opioid addiction treatment by allowing nurse practitioners (NPs) and physician assistants (PAs) in underserved areas to prescribe and dispense buprenorphine.
FDA Announces Efforts to Ease Provider Access to Clinical Trial Info
January 17th 2018The FDA has announced new efforts to enhance transparency around drug approval decisions by launching a pilot program aimed at improving health care providers' access to key information related to new drugs, according to a statement.
FDA: LABA Use with ICS Does Not Increase Risk of Serious Outcomes
December 22nd 2017Officials with the FDA have concluded that treating patients with asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone, prompting removal of a boxed warning about the potential effects.
FDA OKs New GLP-1 Receptor Agonist for Type 2 Diabetes
December 5th 2017The FDA has approved Novo Nordisk's glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic), indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, according to a company announcement.
ACIP Endorses Use of Herpes Zoster Vaccine
October 25th 2017In a narrow 8-7 vote, the Advisory Committee on Immunization Practices (ACIP) endorsed the use of the newly FDA approved zoster vaccine recombinant, adjuvanted (Shingrix, GlaxoSmithKline) over the established zoster vaccine live (Zostavax, Merck).